327 related articles for article (PubMed ID: 25587996)
21. Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
Keepers TR; Gomez M; Celeri C; Nichols WW; Krause KM
Antimicrob Agents Chemother; 2014 Sep; 58(9):5297-305. PubMed ID: 24957838
[TBL] [Abstract][Full Text] [Related]
22. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
[TBL] [Abstract][Full Text] [Related]
23. Emergence of Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in
Fraile-Ribot PA; Del Rosario-Quintana C; López-Causapé C; Gomis-Font MA; Ojeda-Vargas M; Oliver A
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685471
[No Abstract] [Full Text] [Related]
24. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
Ortiz de la Rosa JM; Nordmann P; Poirel L
J Antimicrob Chemother; 2019 Jul; 74(7):1934-1939. PubMed ID: 31225611
[TBL] [Abstract][Full Text] [Related]
25. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
[TBL] [Abstract][Full Text] [Related]
26. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.
Papp-Wallace KM; Becka SA; Zeiser ET; Ohuchi N; Mojica MF; Gatta JA; Falleni M; Tosi D; Borghi E; Winkler ML; Wilson BM; LiPuma JJ; Nukaga M; Bonomo RA
ACS Infect Dis; 2017 Jul; 3(7):502-511. PubMed ID: 28264560
[TBL] [Abstract][Full Text] [Related]
27.
Fraile-Ribot PA; Mulet X; Cabot G; Del Barrio-Tofiño E; Juan C; Pérez JL; Oliver A
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674059
[TBL] [Abstract][Full Text] [Related]
28. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
Sader HS; Huband MD; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
[No Abstract] [Full Text] [Related]
29. A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa.
Sy SKB; Zhuang L; Xia H; Beaudoin ME; Schuck VJ; Nichols WW; Derendorf H
J Antimicrob Chemother; 2018 May; 73(5):1295-1304. PubMed ID: 29415212
[TBL] [Abstract][Full Text] [Related]
30. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
Humphries RM; Yang S; Hemarajata P; Ward KW; Hindler JA; Miller SA; Gregson A
Antimicrob Agents Chemother; 2015 Oct; 59(10):6605-7. PubMed ID: 26195508
[TBL] [Abstract][Full Text] [Related]
31. Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals.
Castanheira M; Doyle TB; Smith CJ; Mendes RE; Sader HS
J Antimicrob Chemother; 2019 Sep; 74(9):2588-2595. PubMed ID: 31225882
[TBL] [Abstract][Full Text] [Related]
32. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
Papp-Wallace KM; Winkler ML; Taracila MA; Bonomo RA
Antimicrob Agents Chemother; 2015 Jul; 59(7):3710-7. PubMed ID: 25666153
[TBL] [Abstract][Full Text] [Related]
33. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.
Sader HS; Castanheira M; Mendes RE; Flamm RK; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2015; 59(6):3656-9. PubMed ID: 25845861
[TBL] [Abstract][Full Text] [Related]
34. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
Nicolau DP
Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
[TBL] [Abstract][Full Text] [Related]
35. Phenotypic and genetic resistance traits of Pseudomonas aeruginosa strains infecting cystic fibrosis patients: A French cohort study.
Courtois N; Caspar Y; Maurin M
Int J Antimicrob Agents; 2018 Sep; 52(3):358-364. PubMed ID: 29775685
[TBL] [Abstract][Full Text] [Related]
36. The activity of ceftazidime/avibactam against carbapenem-resistant
Ito CAS; Bail L; Arend LNVS; Nogueira KDS; Tuon FF
Infect Dis (Lond); 2021 May; 53(5):386-389. PubMed ID: 33423568
[No Abstract] [Full Text] [Related]
37. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
Nolan PJ; Jain R; Cohen L; Finklea JD; Smith TT
Diagn Microbiol Infect Dis; 2021 Feb; 99(2):115204. PubMed ID: 33152675
[TBL] [Abstract][Full Text] [Related]
39. Extended-spectrum and metallo-beta-lactamases among ceftazidime-resistant Pseudomonas aeruginosa in Riyadh, Saudi Arabia.
Al-Agamy MH; Shibl AM; Tawfik AF; Elkhizzi NA; Livermore DM
J Chemother; 2012 Apr; 24(2):97-100. PubMed ID: 22546765
[TBL] [Abstract][Full Text] [Related]
40. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]